Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

G. M. Durie, Brian; Hoering, Antje; Sexton, Rachael; H. Abidi, Muneer; Epstein, Joshua; Vincent Rajkumar, S.; Dispenzieri, Angela; P. Kahanic, Stephen; C. Thakuri, Mohan; J. Reu, Frederic; M. Reynolds, Christopher; Z. Orlowski, Robert; Barlogie, Bart

doi:10.1038/s41408-020-0311-8

Public

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

Shared by NobleBlocks on May 11, 2020 • 12:00 AM UTC

Authors:

Brian G. M. Durie

Antje Hoering

Rachael Sexton

Abstract

Abstract SWOG S0777, a randomized phase III trial, compared bortezomib, lenalidomide and dexamethasone (VRd) with lenalidomide and dexamethasone (Rd). This updated analysis includes 460 patients evaluable for survival endpoints: 225 eligible and analyzable patients were randomized to Rd and 235 to V...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!